

Research Activities Newsletter

September 2022

In the News: Congratulations to the following awardees



Nicholas Felicione, Assistant Professor of Community Health and Health Behavior is PI on a transfer award from the Roswell Park Comprehensive Cancer Center, funded by the National Cancer Institute/NIH. The project, entitled *Personal Factors, Product Characteristics, and Changes in Biomarkers of Exposure Among Cigarette Smokers who Switch to Noncombustible Tobacco Products*. The study's objective is to characterize product transitions among cigarette smokers to evaluate factors associated with transitioning to noncombustibles and assess the potential of noncombustibles as a harm reduction strategy.



Gregory Homish, Professor and Chair of Community Health and Health Behavior is PI on a new training grant from Health Resources & Services Administration/U.S. Dept. of Health and Human Services for the project entitled, *Public Health (PH) PRACTICE: Prepare, Respond And Collaborate To Address Inequities, COVID, and Other Emergencies*. The award will support current and future public health trainees, thereby increasing the public health workforce in medically underserved areas. **Kim Krytus, Heather Orom, Sarahmona Przybyla** are Co-Investigators, along with training support staff consisting of **Mary Glenn, Sarah Heavey, Heather Ochs-Balcom, Miranda Bosse, and Ariana Martinez**.



Michael LaMonte, Research Professor of Epidemiology and Environmental Health is PI on a continuation award from Fred Hutchinson Cancer Center/NHLBI for the project entitled, *Physical Activity to Improve CV Health in Older Women: A Pragmatic Trial*. The study is testing whether a physical activity (PA) intervention designed to increase and/or maintain PA and reduce sedentary behavior will reduce major cardiovascular events in older women.



Schuyler Lawson, Predoctoral Student in Community Health and Health Behavior received a new award from the National Center for Advancing Translational Sciences/NIH (PI: Tim Murphy, Medicine) for the project entitled, *University at Buffalo Clinical and Translational Science Institute – Supplement Schuyler*. The project will examine racial differences in the use of smoking cessation applications (apps) and their association with smoking-related outcomes such as treatment utilization, reductions in cigarettes smoked per day, and smoking abstinence. The sample will consist of regular cigarette smokers drawn from the Population Assessment of Tobacco Health (PATH) study, a nationally representative, longitudinal cohort study.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, is PI on a renewal award from Kaleida Health for the project entitled, *ECRIP: Disparities in Access and Outcomes of Weight Management in Western New York*. The program's goal is to promote the development of new clinical researchers, provide seed funding for future center grants, and support a broad spectrum of research activities around the Center's theme.



Heather Orom, Associate Professor of Community Health and Health Behavior and SPHHP's Associate Dean for Equity, Diversity and Inclusion, is Co-Investigator on a new award from the National Science Foundation (PI: Jennifer Surtees, Biochemistry) for the project entitled, *PIPP Phase I: Center for Ecosystems Data Integration and Pandemic Early Warning Systems*. The project seeks to 1) develop an integrated early warning system based on data and probabilistic modeling of microbial and human ecosystems; and 2) develop community networks that provide infrastructure through which to communicate pandemic risk and develop cultural-responsive approaches to pandemic prevention.



J. Luke Pryor, Clinical Associate Professor of Exercise and Nutrition Science (ENS) is PI on a new award from Advanced Technology International for the project entitled, *Modeling Metabolic Energy Expenditure of Dismounted Female Warfighters in Multi-stressor Environments*. The study seeks to develop a model for predicting metabolic energy expenditure and exhaustion limits in female Warfighters serving in combat roles. The resulting model will enhance the accuracy of metabolic energy expenditure and exhaustion limit estimates, optimize mission planning for modern and future generations of dismounted Warfighters, and ultimately improve performance, pacing, readiness, and non-battle injury resistance. **David Hostler**, Professor and Chair of ENS, **Riana Pryor**, Assistant Professor of ENS, and **Rebecca Begalle**, Clinical Assistant Professor of ENS, are Co-Investigators.



Jean Wactawski-Wende, SUNY Distinguished Professor of Epidemiology and Environmental Health and Dean of SPHHP, is Co-Investigator on a new award from the National Institute of Dental & Craniofacial Research/NIH (PI: Keith Kirkwood, Periodontics and Endodontics) for the project entitled, *Immunometabolic Regulation of MDSCs in Periodontitis*. The study seeks to understand the mechanisms that underpin the links between degree of obesity and periodontal disease incidence.

In This Issue

In the News: Congratulations to the Following Awardees 1
Grant Clinic 2
NIH Funding Opportunities
 Request for Applications (RFA) 4
 Program Announcements Reviews in an Institute (PAR) 10
 NIH Funding Opportunities: Program Announcements (PA)..... 12
Individual Actions for Sustainability 12

Grant Clinic

NIH LOAN REPAYMENT PROGRAMS (LRP) APPLICATION CYCLE OPENED ON SEPTEMBER 1, 2022 and CLOSES ON NOVEMBER 17, 2022.

Awardees can receive up to **\$100,000** of qualified educational debt repayment with a two-year contract.

The NIH LRPs are unique programs, with tremendous benefit to early-stage researchers, so we strongly encourage those that were not successful in getting their applications funded to apply again.

Be sure to visit the LRP website <https://www.lrp.nih.gov/apply> to learn more about eligibility requirements, application dates, and benefits of receiving an NIH LRP award!

GENERAL NOTICES

[NOT-DA-22-079](#)

Notice of Availability of FAQ for RFA-DA-23-011, “Registry of Medical Cannabis Use and Health Outcomes (UM1 – Clinical Trial Optional)”

On June 14, 2022, NIDA issued the FOA [RFA-DA-23-011](#): Registry of Medical Cannabis Use and Health Outcomes (UM1 - Clinical Trial Optional). To assist potential applicants to the above-referenced FOA, this Notice provides information regarding the availability of a Frequently Asked Questions (FAQ) document. The FAQ is available on the NIDA Web site at [NIDA Funding Opportunities | National Institute on Drug Abuse \(NIDA\) \(nih.gov\)](#). All applicants are encouraged to review the FAQ prior to submitting their application.

[NOT-RM-23-004](#)

Notice of Information: Announcing NIH Community Partnerships to Advance Science for Society (ComPASS) Program: Community-Led, Health Equity Structural Intervention Initiative (CHESI) Research Opportunity Announcement (ROA) and Technical Assistance Webinar

The purpose of this announcement is to inform community organizations about the new research opportunity, [OTA-22-007](#). This research opportunity will fund community organizations and support the development, implementation, assessment, and dissemination of community-led, health equity [structural interventions](#), co-created in partnership with research organizations, that intervene upon structural factors that produce and perpetuate health disparities. **Letter of Intent (Required) are due:** November 18, 2022

[NOT-OD-22-206](#)

Additional Awards Eligible for PA-21-071 “Research Supplements to Promote Diversity in Health-Related Research” (Admin Supp)

The purpose of this Notice is to add an activity code to the list of eligible awards that may apply for supplements through “Research Supplements to Promote Diversity in Health-Related Research” (Admin Supp - Clinical Trial Not Allowed) ([PA-21-071](#)).

[NOT-AT-22-026](#)

Request for Information (RFI): Investigators’ Interests in and Barriers to Research Studies on the Health Effect of Cannabis and its Constituents

The purpose of this RFI is to solicit information from the scientific research community about its interest in and barriers to research on the health effects of cannabis and its constituents. NIH is interested in gathering information about barriers, scientific interests, and needs associated with therapeutic cannabis or cannabinoid research from investigators conducting or interested in conducting research on cannabis, cannabinoid phytochemical constituents, and related compounds (synthetic compounds, terpenes etc.).

[NOT-OD-22-213](#)

Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data

This supplemental information was developed to address comments on the draft DMS Policy requesting further clarity and direction for researchers and their institutions about NIH’s principles and preferred practices regarding privacy.[3] It was revised in response to comments received to the “Request for Public Comments on DRAFT Supplemental Information to the NIH Policy for Data Management and Sharing: Protecting Privacy When Sharing Human Research Participant Data” ([NOT-OD-22-131](#)).[4] NIH considered all feedback in the development of the final supplemental information. Changes made in response to the public comments are summarized in the Notice.

NOTICE OF INTENT TO PUBLISH

[NOT-CA-22-126](#) (R25, Clinical Trial Not Allowed)

FOA for Transformative Educational Advancement and Mentoring Network (TEAM)

The purpose of this Notice is to announce the NCI's intention to issue a FOA as a Request for Applications for the Transformative Educational Advancement and Mentoring Network (TEAM) (R25). The overarching goal of this R25 program is to support research and educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. The FOA is expected to be published October 28, 2022 with an expected application due date February 10, 2023.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-OD-22-166](#) – **Research on the Health of Bisexual and Bisexual+ People**

This NOSI is specifically intended to stimulate investigation into the biomedical, clinical, behavioral, and social processes that affect the health and welfare of bi/bi+ individuals, and the development of acceptable, appropriate, and relevant interventions, preventive strategies, and service delivery methods. This Notice applies to due dates on or after September 25, 2022, and subsequent receipt dates through May 8, 2025.

[NOT-OD-22-203](#) – **Development and Preliminary Testing of Health-related Behavioral Interventions**

This Notice encourages behavioral intervention research that integrates basic behavioral and social science, that create, refine, and test innovative interventions focused on the initiation, cessation, or maintenance of behaviors associated with improved health or disease mitigation. This Notice applies to due dates on or after October 3, 2022, and subsequent receipt dates through September 26, 2024.

[NOT-HD-22-043](#) – **Implementation Science to Advance Maternal Health and Maternal Health Equity for the IMPROVE initiative**

The purpose of this NOSI is to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality (MMM). This NOSI will support the development and implementation of strategies to inform integrated efforts involving policy and practice changes to improve preconception, pregnancy, perinatal, and postpartum care and advance maternal health and maternal health equity. This Notice applies to due dates on or after February 6, 2023, and subsequent receipt dates through May 7, 2025.

[NOT-AG-22-030](#) – **Small Research Grants for Innovations in Health Longevity Research**

This NOSI invites applications for small research grants that align with the goals of the National Academy of Medicine's [Healthy Longevity Grand Challenge](#), as well as the National Institute on Aging's (NIA) interests in supporting research to promote a long healthspan and functional independence in both aging and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This Notice applies to due dates on or after February 16, 2023, and subsequent receipt dates through May 7, 2023.

[NOT-OD-22-208](#) – **Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp clinical Trial Optional)**

The Office of Research on Women's Health ([ORWH](#)) announces the availability of administrative supplements to support research highlighting health inequities among women in the US who are understudied, underrepresented and under reported (U3) in biomedical research. This NOSI encourages rigorous experimental designs, as well as the implementation of collaborative interdisciplinary research on the common causes and pathways of ill health and disease, differential risk, morbidity, and mortality, across socioecological domains and levels of influence. **Applications must be received by:** January 31, 2023

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

NOVEMBER 2022 DUE DATES

[RFA-DA-23-048](#) (R61/R33 Clinical Trial Required)

HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers

This FOA seeks to address the urgency and magnitude of the opioid crisis in populations that experience health disparities by developing and testing new or adapted interventions to prevent opioid misuse among patients served by community health centers (CHCs), and/or by developing and testing implementation

strategies for screening and referral to preventive interventions for misuse of opioids and other substances among patients served by CHCs. **Application Due Date:** November 9, 2022

[RFA-MD-22-008](#) (R01, Clinical Trials Optional)

Understanding and Addressing Misinformation among Populations that Experience Health Disparities

This initiative seeks to stimulate multi-level research (see [NIMHD Research Framework](#)) to understand and mitigate the harmful impacts of misinformation and disinformation among populations that experience health disparities and to inform public health practice. Examples include COVID-19, HIV/AIDS, STIs, vaccines, genetic testing, cancer, and tobacco use and cessation, among others. **Application Due Date:** November 13, 2022

[RFA-DA-23-015](#) (R01, Clinical Trial Not Allowed)

Transformative Research on the Basic Mechanisms of Polysubstance Use in Addiction

NIDA seeks to stimulate innovative research that will transform our understanding of the basic mechanisms that underlie polysubstance use in addiction. These studies will investigate novel neurobiological, pharmacological and/or behavioral mechanisms that drive the behavioral and pharmacological profiles observed following polysubstance use. **Application Due Date:** November 14, 2022

[RFA-AA-22-001](#) **Specialized Alcohol Research Centers** (P50, Clinical Trial Optional)

[RFA-AA-22-002](#) **Comprehensive Alcohol Research Centers** (P60, Clinical Trial Optional)

NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. The Centers are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research. **Application Due Date:** November 15, 2022

[RFA-DA-23-025](#) (U24 clinical Trial Not Allowed)

NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research

NIDA seeks applications for a Coordination Center to establish a learning community to maximize the impact of NIDA's Racial Equity Initiative research projects. NIDA has issued several REI FOAs to support highly innovative, solution-focused research studies to address persistent disparities in the United States affecting racial and ethnic minority communities. These disparities in outcomes related to substance use, consequences of substance use, and substance use disorder prevention and treatment, are driven by social, structural, and systemic factors. Thus, effective solutions should be grounded in an understanding of these factors and responsive to the needs of communities and resources available within communities. **Application Due Date:** November 15, 2022

[RFA-DA-23-011](#) (UM1 – Clinical Trial Optional)

Registry of Medical Cannabis Use and Health Outcomes

NIDA seeks applications to develop and maintain a medicinal cannabis use registry to assess the medical conditions reported as reasons for using medicinal cannabis, how and what products are being used, and the associated medical outcomes. The goal of this registry is to inform research, policy, and clinical recommendation practices on medicinal cannabis, associated conditions, and outcomes.

Application Due Date: November 16, 2022

NCI's Informatics Technology for Cancer Research Program FOAs (Clinical Trial Optional):

[RFA-CA-22-021](#) (R21) **Development of Innovative Informatics Methods and Algorithms**

[RFA-CA-22-022](#) (U01) **Early Stage Development of Informatics Technologies**

[RFA-CA-22-023](#) (U24) **Advanced Development of Informatics Technologies**

[RFA-CA-22-024](#) (U24) **Sustained Support for Informatics Technologies**

The program supports the development of critical tools and resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. **Application Due Date:** November 17, 2022

[RFA-DK-22-014](#) (U01 – Clinical Trial Required)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities

This FOA invites applications for **Intervention Sites** that will work collaboratively with a Research Coordinating Center (RCC) (see [RFA-DK-22-015](#)) to develop and test meaningful interventions that aim to

dismantle or mitigate the effects of structural racism to reduce kidney health disparities. **Application Due Date:** November 18, 2022

[RFA-DK-22-015](#) (U24 – Clinical Trial Not Allowed)

Interventions that Address Structural Racism to Reduce Kidney Health Disparities – Research Coordinating Center

This Funding Opportunity Announcement (FOA) invites applications for the Research Coordinating Center (RCC) that will lead, manage, and harmonize efforts for the Consortium. **Application Due Date:** November 18, 2022

[RFA-CA-22-041](#) (F99/K00 Clinical Trial Not Allowed)

The NCI Predoctoral to Postdoctoral Fellow Transition Award

The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. **Application Due Date:** November 18, 2022

[RFA-NR-23-001](#) (UG3/UH3, Clinical Trials Required)

HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations

This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to accelerate implementation of effective non-opioid interventions for pain management in rural and remote populations. The overall goal of this initiative is to support the implementation of effective practices and procedures that may lead to prevention or improved management of chronic pain in rural and/or remote populations, along with a reduction in prescribing and/or using opioids. **Application Due Date:** November 21, 2022

[RFA-HD-23-008](#) (UG1 Clinical Trial Optional)

NICHD Global Network for Women’s and Children’s Health Research: Research Units

[RFA-HD-23-009](#) (U24 Clinical Trial Optional)

NICHD Global Network for Women’s and Children’s Health Research: Data Coordinating Center

The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) invites U.S. institutions in partnership with research centers in low and middle-income countries to submit applications as Research Units (RUs) to participate in the Global Network for Women’s and Children’s Health Research. RUs will consist of U.S.-based research centers applying in partnership with research centers in low- and lower middle-income countries as defined by the World Bank. The RU grantees will become part of a cooperative network in scientific partnership with the NIH to conduct multi-center observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-constrained settings to address the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality. **Application Due Date:** November 30, 2022

DECEMBER 2022 DUE DATES

[RFA-HS-22-010](#) (T32)

AHRQ National Research Service Award (NRSA) Institutional Research Training Grant

The objective of the NRSA T32 program is to develop and/or enhance research training opportunities for individuals interested in careers in health services, behavioral, and clinical research that are relevant to the AHRQ mission. The training program is designed to provide didactic and/or experiential training for predoctoral and postdoctoral trainees interested in: (1) improving clinical practice or the health care system's ability to provide access to and delivery of high quality, high-value health care; and/or (2) providing policymakers with the ability to assess the impact of system changes on outcomes, quality, access to, cost, and use of health care services. AHRQ strongly encourages the submission of applications in response to this NOFO from a diverse group of applicant institutions and the training of a diverse cadre of trainees. **Application Due Date:** December 1, 2022

[RFA-HD-23-035](#) (U54 Clinical Trial Optional)

Maternal Health Research Centers of Excellence

This FOA runs in parallel with companion FOAs that seek applications for an Implementation Science Hub/Resource Center ([RFA-HD-23-037](#)) and a Data Innovation and Coordinating Hub/Resource Center ([RFA-HD-23-036](#)). The goal of this initiative is for trans-disciplinary research teams to conduct multi-layered novel

research projects that will have the potential to drastically reduce pregnancy-related and pregnancy-associated maternal deaths and decrease SMM. **Application Due Date:** December 5, 2022

[RFA-HD-23-036](#) (U24 Clinical Trial Not Allowed)

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center

This FOA seeks applications for the Data Innovation and Coordinating Hub/Resource Center for the Maternal Health Research Centers of Excellence initiative. This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence ([RFA-HD-23-035](#)) and an Implementation Science Hub/Resource Center ([RFA-HD-23-037](#)). Investigators with broad expertise and experience in providing an environment of excellence in clinical and public health informatics and in maximizing data comparability with projects proposed in the Research Centers to facilitate harmonization with existing large-scale research efforts should consider applying. **Application Due Date:** December 5, 2022

[RFA-HD-23-037](#) (U24 Clinical Trial Optional)

Maternal Health Research Centers of Excellence Implementation Science Hub/Resource Center

This FOA runs in parallel with companion FOAs that seek applications for Research Centers of Excellence ([RFA-HD-23-035](#)) and a Data Innovation and Coordinating Hub/Resource Center ([RFA-HD-23-036](#)). This FOA seeks applications from investigators with demonstrated expertise in maternal health related implementation science, including but not limited to implementation science conceptual frameworks and hybrid-effectiveness implementation design, expertise in disseminating information to diverse audiences/interested parties, serving as an implementation science consultant, integrating data elements, including needs assessments, leading process evaluations, and aiding in the design of implementation-focused sub-studies. **Application Due Date:** December 5, 2022

[RFA-OH-23-001](#) (R21)

Exploratory/Developmental Grants Related to the World Trade Center Health Program

NIOSH supports exploratory and developmental research projects that address issues related to diagnostic or treatment uncertainty with respect to individuals receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 Health and Compensation Act of 2010 ([Public Law 111-347](#), as amended by Public Laws [114-113](#) and [116-59](#)). Enrolled WTC responders and certified-eligible WTC survivors will be included in the research project. Projects should support and facilitate the feasibility, development, and evaluation of methods, practices, interventions, and programs related to Lifestyle Medicine within the following clinical research areas: treatment research, program evaluation, screening research and health equity. **Application Due Date:** December 12, 2022

FEBRUARY 2023 DUE DATES

[RFA-DA-23-045](#) (UG1 – Clinical Trial Not Allowed)

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats

The goal of this FOA is to seek research to promote rapid development of analytical methods and tools to assess the prevalence of emerging illicit drugs and thereby understand their health impacts. This FOA is part of the NIH's Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at <https://heal.nih.gov/>. **Application Due Date:** February 3, 2023

[RFA-DA-23-046](#) (RM1 – Clinical Trial Optional)

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On

NIDA seeks applications for multi-project RM1 Opioid Use Disorder Quality Measurement and Management Research Centers (OUD-QM²RCs). OUD-QM²RCs will involve researchers and a partner with a deployed or in-development quality measurement strategy for opioid use disorder treatment that rigorous, scientific research could substantially advance. The ultimate goal is the creation of feasible, efficient quality measurement systems that provide meaningful information to help patients, families, and payors fairly compare and select providers and to help clinicians and providers improve patient outcomes. **Application Due Date:** February 3, 2023

[RFA-DA-23-051](#) (R01 – Clinical Trials Optional)

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social

Determinants

Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. Research should be conducted within populations disproportionately affected by opioid use disorder, mental illness or death by suicide. Applications must involve populations disproportionately affected by opioid-related harms and take place within the U.S. and its territories. Applications should test scalable, high-impact strategies that will contribute to ending the opioid crisis. **Application Due Date:** February 3, 2023

[RFA-CA-22-035](#) (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-CA-22-036](#) (K99/R00 – Independent Clinical Trial Required)

[RFA-CA-22-037](#) (K99/R00 – Independent Basic Experimental Studies with Humans Required)

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers

This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to work with their institutions to apply. **Application Due Date:** February 28, 2023

MULTIPLE DUE DATES

[RFA-CA-22-050](#) (R01 Clinical Trial Optional)

NCI Cancer Moonshot Scholars Diversity Program (CMSDP)

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. **Application Due Dates:** November 8, 2022, June 6, 2023, February 6, 2024

[RFA-DA-23-013](#) (R01 Clinical Trial Optional)

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV. Research projects should demonstrate that they will have a major impact in improving outcomes related to substance misuse, with a goal of identifying or targeting strategies to prevent, reduce, or eliminate racial and/or ethnic disparities in substance use outcomes. **Application Due Dates:** November 14, 2022, November 14, 2023, November 14, 2024

[RFA-DA-23-023](#) (R01 Clinical Trial Optional)

[RFA-DA-23-024](#) (R34 Clinical Trial Optional)

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations

The purpose of this initiative is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged. **Application Due Dates:** November 14, 2022, November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) (DP1 Clinical Trial Optional)

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make

exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. **Application Due Dates:** November 14, 2022, November 14, 2023, November 14, 2024

[RFA-DA-23-028](#) (R61/R33 Clinical Trial Optional)

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. Applications are strongly encouraged to incorporate a multidimensional and intersectional approach to understanding structural racism, including but not limited to factors such as income inequality, inequities of homeownership, employment, education, incarceration, area deprivation, food insecurity, and neighborhood segregation. In addition to neuroscience/psychology, all applications are expected to incorporate expertise as needed from fields including but not limited to epidemiology, intervention science, community-engaged research, sociology, and/or ethnic studies. **Application Due Dates:** November 14, 2022, November 14, 2023, November 14, 2024

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. This FOA invites phased applications to support projects for which preliminary or feasibility data is not available at the time of submission. This FOA is a companion to [RFA-DA-23-054](#), which solicits applications for which pilot data is available. **Application Due Dates:** November 14, 2022, March 20, 2023, November 15, 2023, March 20, 2024

[RFA-EB-21-001](#) (R01, Clinical Trial Optional)

Technology Development to Reduce Health Disparities

This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities. **Application Due Dates:** January 26, 2023, January 26, 2024

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: February 14, 2023, October 13, 2023, February 13, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support

and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nhlbi.nih.gov.

Application Due Dates: June 20, 2023; October 19, 2023, June 20, 2024; and October 21, 2024.

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.

Application Receipt Dates: Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

NCI Outstanding Investigator Award

The Outstanding Investigator Award (R35) is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. Applicants should describe a general research strategy, providing an overview of the broad research questions/scientific questions they plan to address, a general description of possible strategies, and a description of how their past scientific accomplishments will inform this research. Experimental details, extensive preliminary data, and specific aims should not be included unless critical to assessing the feasibility of the new avenues of research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical

therapeutic and diagnostic devices, including software as a medical device. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-22-233](#) (R61/R33 Clinical Trial Not Allowed)

Time-Sensitive Opportunities for Health Research

This FOA establishes an accelerated review/award process to support novel behavioral and social science research to understand health outcomes related to an unexpected and/or time-sensitive event. Applications in response to this FOA must demonstrate that the research proposed is time-sensitive and must be initiated with minimum delay due to a limited window of opportunity to collect baseline data, answer key research questions, and/or prospectively evaluate a new policy or program that will likely impact health-related behavior or health outcomes in a given population. **Application Due Date:** November 2, 2023

[PAR-23-024](#) (DP1 – Clinical Trial Optional)

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV comorbidities, Coinfections, and Complications

The award is intended to support innovative, high-impact, research by early stage investigators that will open new areas of HIV/AIDS research related to CCCs within the mission of one or more of the NIH components participating in this FOA. Areas of interest include novel mechanistic research into pathogenic processes, identification of novel preventive or therapeutic targets, interventions, or therapies; novel approaches to delineate unique biological pathways for HIV-associated CCCs in PWH as compared to those CCCs in people without HIV; pathogenesis of multimorbid HIV-associated CCCs; and/or identification of unique potential drug targets in PWH. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 2, 2025

[PAR-22-216](#) (R21 Clinical Trial Optional)

NCI Clinical and Translational Exploratory/Developmental Studies

The purpose of this FOA is to promote innovative preclinical, early phase clinical, and correlative studies that are hypothesis-driven and based upon established basic cancer research discoveries. This FOA will support exploratory/developmental projects in the advancement of novel anti-cancer agents, diagnostic tools, correlative biomarker identification, clinical approaches in treatment, symptom management, and prevention of common or rare tumors, as well as research on cancer disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** July 2, 2025

[PAR-22-173](#) (R34, Clinical Trials Optional)

[PAR-22-174](#) (U34 Clinical Trials Optional)

Cancer Prevention and Control Clinical Trials Planning Grant Program

The National Cancer Institute (NCI) intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2025

[PAR-22-201](#) (P01 Clinical Trial Optional)

NIDA Program Project Grant Applications

Program projects are expected to be broadly based investigative efforts with a clear, well-defined, and unifying goal or theme to establish the direction, objectives that address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse. A Program must be comprised of at least three inter-related research projects judged to be independently scientifically meritorious, complementary of one another, and demonstrate an essential element of unity and interdependence. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** September 8, 2025

[PAR-22-210](#) (R01 Clinical Trial Optional)

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants

The FOA will also expand the scope and reach of projects supported through the Research to Action program (<https://www.niehs.nih.gov/research/supported/translational/rta/cfg/index.cfm>). The main objectives of this program remain the same as prior solicitations: 1) promote community engagement in environmental health research, 2) support multi-disciplinary research to collect and characterize information about environmental health concerns of significance to a community, and 3) stimulate research translation and dissemination to community members, public health professionals and/or policymakers to inform an action that will ultimately promote the reduction of exposure(s) and reduce the health impact from environmental stressors. To meet these stated objectives, applicants must propose CEnR projects that incorporate all three elements: community engagement, research, and public health action. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** September 8, 2025

[PAS-22-206](#) (K01 – Clinical Trial Required)

[PAS-22-207](#) (K23 – Clinical Trial Required)

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment

This FOA is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. Applicants should focus on testing implementation strategies to improve the quality, effectiveness, availability, and affordability of substance use prevention or treatment services; to promote their integration and accessibility across a variety of settings (e.g., specialty care, primary care, schools, workplaces, and other nontraditional healthcare and community settings); and to promote equity in access and outcomes. **Application Due Dates:** Multiple Due Dates; see announcement. **Expiration Date:** November 13, 2025

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates:

[PA-22-251](#)

Agency for Healthcare Research and Quality (AHRQ)-sponsored National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)

Expiration Date: August 9, 2025

[PA-22-255](#)

AHRQ Mentored Research Scientist Career Development Award (K01)

Expiration Date: November 10, 2025

[PA-22-238](#)

AHRQ Conference Grant Programs (R13)

Expiration Date: November 1, 2026.

[PA-22-232](#)

AHRQ Mentored Clinical Scientist Research Career Development Award (K08)

Expiration Date: February 14, 2027

Individual Actions for Sustainability



If you are purchasing online and don't need the item(s) right away, consider selecting a longer shipping time. This practice reduces the amount of GHG emission produced when delivering your item(s). Over time, this benefits our world.

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras